| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Kissei Pharmaceutical Co. Ltd (F: KIS)
KIS Technical Analysis
5
| As on 12th Nov 2021 KIS SHARE Price closed @ 0.18 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 15.94 & Strong Sell for SHORT-TERM with Stoploss of 16.88 we also expect STOCK to react on Following IMPORTANT LEVELS. |
KISSHARE Price
| Open | 0.18 | Change | Price | % |
| High | 0.18 | 1 Day | 0.00 | 0.00 |
| Low | 0.18 | 1 Week | 0.04 | 28.57 |
| Close | 0.18 | 1 Month | 0.01 | 5.88 |
| Volume | 3833770 | 1 Year | -18.52 | -99.04 |
| 52 Week High 20.80 | 52 Week Low 0.14 | ||||
F Germany Most Active Stocks
| ENB | 47.60 | -0.92% |
| TEF | 3.84 | -0.52% |
| TEF | 3.84 | -0.52% |
| WHL | 5150.00 | -0.44% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| WDI | 0.05 | -37.50% |
| TOE | 0.02 | 0.00% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
| KIS Daily Charts |
KIS Intraday Charts |
Whats New @ Bazaartrend |
KIS Free Analysis |
|
|
KIS Important Levels Intraday
| RESISTANCE | 0.18 |
| RESISTANCE | 0.18 |
| RESISTANCE | 0.18 |
| RESISTANCE | 0.18 |
| RESISTANCE | 0.18 |
| RESISTANCE | 0.18 |
| RESISTANCE | 0.18 |
| RESISTANCE | 0.18 |
KIS Forecast April 2024
| 4th UP Forecast | 1.72 |
| 3rd UP Forecast | 1.23 |
| 2nd UP Forecast | 0.92 |
| 1st UP Forecast | 0.62 |
| 1st DOWN Forecast | -0.26 |
| 2nd DOWN Forecast | -0.56 |
| 3rd DOWN Forecast | -0.87 |
| 4th DOWN Forecast | -1.36 |
KIS Weekly Forecast
| 4th UP Forecast | 1.72 |
| 3rd UP Forecast | 1.23 |
| 2nd UP Forecast | 0.92 |
| 1st UP Forecast | 0.62 |
| 1st DOWN Forecast | -0.26 |
| 2nd DOWN Forecast | -0.56 |
| 3rd DOWN Forecast | -0.87 |
| 4th DOWN Forecast | -1.36 |
KIS Forecast2024
| 4th UP Forecast | 39.99 |
| 3rd UP Forecast | 27.22 |
| 2nd UP Forecast | 19.33 |
| 1st UP Forecast | 11.44 |
| 1st DOWN Forecast | -11.08 |
| 2nd DOWN Forecast | -18.97 |
| 3rd DOWN Forecast | -26.86 |
| 4th DOWN Forecast | -39.63 |
Kissei Pharmaceutical Co. Ltd ( F Germany Symbol : KIS )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
KIS Business Profile
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan. Address: 19-48, Yoshino, Matsumoto, Japan, 399-8710
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service